Insulet's Omnipod 5 Automated Insulin Delivery System Receives FDA Clearance For Type 2 Diabetes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 27 2024
0mins
Should l Buy PODD?
Source: Business Insider
FDA Approval: Insulet Corp. has received FDA approval for the SmartAdjust Omnipod 5, the first automated insulin delivery system specifically designed for adults with Type 2 diabetes, featuring a tubeless design and continuous glucose monitoring.
Clinical Study Results: A clinical study involving 289 participants showed significant improvements in blood sugar control, with an average reduction in HbA1c levels, and no serious adverse events reported during the trial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 160.400
Low
316.00
Averages
375.83
High
450.00
Current: 160.400
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INSULET CORP: RBC Lowers Price Target to $280 from $325
- RBC Cuts Target Price: RBC has reduced the target price for Insulet Corporation from $325 to $280.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Insulet's performance.
See More
Insulet Reports Strong Q1 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Insulet reported total Q1 revenue of $762 million, reflecting a 34% year-over-year increase, with U.S. growth at 28% and international growth at 45%, indicating strong global market performance that is expected to enhance future market share.
- Raised Full-Year Guidance: The company raised its FY2026 total revenue growth outlook from 20%-22% to 21%-23%, while also increasing international Omnipod revenue growth expectations from 24%-26% to 26%-28%, demonstrating management's confidence in sustained demand and performance.
- Product Integration and Innovation: The upcoming integration with the Libre 3 Plus Sensor will benefit nearly 450,000 diabetes patients, alongside updates to the Omnipod 5 algorithm, which are anticipated to enhance product competitiveness and user experience, driving sales growth.
- Share Buybacks and Cash Flow: In Q1, the company repurchased approximately 1.25 million shares for $300 million and generated about $90 million in free cash flow, reflecting a proactive strategy in capital management and shareholder returns.
See More
Insulet Reports Q1 Earnings Exceeding Expectations
- Strong Performance: Insulet's Q1 non-GAAP EPS of $1.42 surpassed expectations by $0.23, indicating robust market performance that is likely to boost investor confidence moving forward.
- Significant Revenue Growth: The company reported revenue of $761.7 million, a 33.9% year-over-year increase, exceeding market expectations by $31.6 million, reflecting sustained demand and market share expansion for Insulet's products.
- Positive Future Outlook: For Q2 and FY 2026, Insulet provided optimistic revenue guidance, projecting U.S. Omnipod growth of 18%-20% and international growth of 28%-30%, demonstrating the company's confidence in future market conditions.
- Improved Profitability Metrics: The adjusted operating margin is expected to expand by approximately 100 basis points year-over-year, with adjusted EPS growth exceeding 25%, further enhancing the company's financial health and investment appeal.
See More
Insulet Scheduled to Announce Q1 Earnings on May 6
- Earnings Announcement Schedule: Insulet (PODD) is set to release its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $1.19, reflecting a 16.7% year-over-year growth, indicating the company's ongoing potential for profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $730.1 million, representing a 28.3% year-over-year increase, showcasing Insulet's robust performance in market demand and product sales, further solidifying its position in the medical device industry.
- Historical Performance Review: Over the past two years, PODD has beaten EPS estimates 75% of the time and has surpassed revenue estimates 100% of the time, enhancing investor confidence in the company's future growth prospects due to this consistent performance.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen 9 upward revisions and 8 downward adjustments, while revenue estimates experienced 15 upward revisions and 2 downward adjustments, indicating analysts' optimistic outlook on Insulet's future performance despite some uncertainties.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
Market Update: Analysis of Key Company Performances
- Critical Metals Insight: Critical Metals suggests that to invest in the sector, one must buy MP Materials, indicating a reliance on industry leaders that could influence investor choices and market dynamics.
- SoundHound AI Exit Strategy: SoundHound AI has stated it will not participate in certain businesses, reflecting a reevaluation of its future strategy, which may raise investor concerns about its long-term growth potential.
- Dave's Product Shift: Dave plans to sell its fintech business to focus on energy bars, indicating a significant shift in market positioning that could affect its brand image and market share.
- Rivian's Quarterly Performance: Rivian Automotive expressed surprise at its last quarter's performance, believing the company is on track for profitability, which could boost investor confidence and drive stock price increases.
See More
INSULET CORP: RBC Lowers Price Target to $280 from $325
- RBC Cuts Target Price: RBC has reduced the target price for Insulet Corporation from $325 to $280.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Insulet's performance.
See More
Insulet Reports Strong Q1 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Insulet reported total Q1 revenue of $762 million, reflecting a 34% year-over-year increase, with U.S. growth at 28% and international growth at 45%, indicating strong global market performance that is expected to enhance future market share.
- Raised Full-Year Guidance: The company raised its FY2026 total revenue growth outlook from 20%-22% to 21%-23%, while also increasing international Omnipod revenue growth expectations from 24%-26% to 26%-28%, demonstrating management's confidence in sustained demand and performance.
- Product Integration and Innovation: The upcoming integration with the Libre 3 Plus Sensor will benefit nearly 450,000 diabetes patients, alongside updates to the Omnipod 5 algorithm, which are anticipated to enhance product competitiveness and user experience, driving sales growth.
- Share Buybacks and Cash Flow: In Q1, the company repurchased approximately 1.25 million shares for $300 million and generated about $90 million in free cash flow, reflecting a proactive strategy in capital management and shareholder returns.
See More
Insulet Reports Q1 Earnings Exceeding Expectations
- Strong Performance: Insulet's Q1 non-GAAP EPS of $1.42 surpassed expectations by $0.23, indicating robust market performance that is likely to boost investor confidence moving forward.
- Significant Revenue Growth: The company reported revenue of $761.7 million, a 33.9% year-over-year increase, exceeding market expectations by $31.6 million, reflecting sustained demand and market share expansion for Insulet's products.
- Positive Future Outlook: For Q2 and FY 2026, Insulet provided optimistic revenue guidance, projecting U.S. Omnipod growth of 18%-20% and international growth of 28%-30%, demonstrating the company's confidence in future market conditions.
- Improved Profitability Metrics: The adjusted operating margin is expected to expand by approximately 100 basis points year-over-year, with adjusted EPS growth exceeding 25%, further enhancing the company's financial health and investment appeal.
See More
Insulet Scheduled to Announce Q1 Earnings on May 6
- Earnings Announcement Schedule: Insulet (PODD) is set to release its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $1.19, reflecting a 16.7% year-over-year growth, indicating the company's ongoing potential for profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $730.1 million, representing a 28.3% year-over-year increase, showcasing Insulet's robust performance in market demand and product sales, further solidifying its position in the medical device industry.
- Historical Performance Review: Over the past two years, PODD has beaten EPS estimates 75% of the time and has surpassed revenue estimates 100% of the time, enhancing investor confidence in the company's future growth prospects due to this consistent performance.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen 9 upward revisions and 8 downward adjustments, while revenue estimates experienced 15 upward revisions and 2 downward adjustments, indicating analysts' optimistic outlook on Insulet's future performance despite some uncertainties.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
Market Update: Analysis of Key Company Performances
- Critical Metals Insight: Critical Metals suggests that to invest in the sector, one must buy MP Materials, indicating a reliance on industry leaders that could influence investor choices and market dynamics.
- SoundHound AI Exit Strategy: SoundHound AI has stated it will not participate in certain businesses, reflecting a reevaluation of its future strategy, which may raise investor concerns about its long-term growth potential.
- Dave's Product Shift: Dave plans to sell its fintech business to focus on energy bars, indicating a significant shift in market positioning that could affect its brand image and market share.
- Rivian's Quarterly Performance: Rivian Automotive expressed surprise at its last quarter's performance, believing the company is on track for profitability, which could boost investor confidence and drive stock price increases.
See More
